SGTX · Sigilon Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 |
|---|---|---|
| Revenue | $12.94M | $13.37M |
| Cost of Revenue | - | - |
| Gross Profit | - | - |
| R&D | $37.63M | $53.49M |
| SG&A | $18.98M | $12.53M |
| Total Operating Expenses | $56.61M | $66.02M |
| D&A | $1.26M | $854.0K |
| Operating Income | ($43.67M) | ($52.64M) |
| Interest Expense | $2.29M | $1.20M |
| Income Tax | $0 | $0 |
| Net Income | ($43.56M) | ($77.31M) |
| EPS - Basic | ($1.34) | ($7.55) |
| EPS - Diluted | ($1.34) | ($7.55) |
Balance Sheet
| Line item | FY 2022 | FY 2021 |
|---|---|---|
| Cash & Equivalents | $42.07M | $107.14M |
| Accounts Receivable | $2.17M | $59.0K |
| Inventory | - | - |
| Accounts Payable | $936.0K | $2.34M |
| Current Assets | $74.41M | $126.39M |
| Total Assets | $87.28M | $144.37M |
| Current Liabilities | $30.99M | $34.89M |
| Long-term Debt | $12.02M | $18.41M |
| Total Liabilities | $48.14M | $67.21M |
| Stockholders' Equity | $39.14M | $77.16M |
| Retained Earnings | ($256.80M) | ($213.24M) |
Cash Flow
| Line item | FY 2022 | FY 2021 |
|---|---|---|
| Operating Cash Flow | ($51.47M) | ($61.65M) |
| Investing Cash Flow | ($12.08M) | ($972.0K) |
| Financing Cash Flow | ($1.61M) | $189.40M |
| CapEx | $537.0K | $972.0K |
| Free Cash Flow | ($52.01M) | ($62.62M) |
Ratios
| Metric | FY 2022 | FY 2021 |
|---|---|---|
| Profitability | ||
| Gross margin | - | - |
| Operating margin | -337.3% | -393.6% |
| EBITDA margin | -327.6% | -387.2% |
| Net margin | -336.5% | -578.1% |
| Free cash flow margin | -401.8% | -468.2% |
| FCF / Net income | 1.19 | 0.81 |
| R&D / Revenue | 290.7% | 399.9% |
| SG&A / Revenue | 146.6% | 93.7% |
| Effective tax rate | - | - |
| Return on assets | -49.9% | -53.6% |
| Return on equity | -111.3% | -100.2% |
| Return on invested capital | -67.4% | -43.5% |
| Liquidity | ||
| Current ratio | 2.40 | 3.62 |
| Quick ratio | 2.40 | 3.62 |
| Cash ratio | 1.36 | 3.07 |
| Leverage | ||
| Debt / Equity | 0.31 | 0.24 |
| Debt / Assets | 0.14 | 0.13 |
| Debt / EBITDA | - | - |
| Interest coverage | -19.1x | -43.8x |
| Equity multiplier | 2.23 | 1.87 |
| Liabilities / Assets | 0.55 | 0.47 |
| Efficiency | ||
| Asset turnover | 0.15 | 0.09 |
| Inventory turnover | - | - |
| Days sales outstanding | 61d | 2d |
| Days inventory outstanding | - | - |
| Days payable outstanding | - | - |
| Cash conversion cycle | - | - |
| Valuation | ||
| P / E | - | - |
| P / B | - | - |
| P / S | - | - |
| EV / EBITDA | - | - |
| Growth | ||
| Revenue growth (YoY) | -3.2% | - |
| Revenue CAGR (3y) | - | - |
| Revenue CAGR (5y) | - | - |
| Gross profit growth (YoY) | - | - |
| Operating income growth (YoY) | 17.1% | - |
| Net income growth (YoY) | 43.7% | - |
| EPS growth (YoY) | 82.3% | - |
| EPS CAGR (3y) | - | - |
| EPS CAGR (5y) | - | - |
| FCF growth (YoY) | 16.9% | - |
| FCF CAGR (5y) | - | - |
| Book value growth (YoY) | -49.3% | - |
Stability scores
Altman Z′
FY 2022 · bankruptcy risk
-3.20
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2022 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✗Cash flow > net income
- ✓Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Sigilon Therapeutics against the 5 most active filers in the same SIC group.